Products Categories
| CAS No.: | 74578-69-1 |
|---|---|
| Name: | Ceftriaxone sodium |
| Article Data: | 12 |
| Molecular Structure: | |
|
|
|
| Formula: | C18H18N8Na2O7S3 |
| Molecular Weight: | 598.552 |
| Synonyms: | 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-,disodium salt, [6R-[6a,7b(Z)]]-;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-,disodium salt, (6R,7R)- (9CI);Acantex;Cefatriaxone;Ceftriaxone disodium;Ceftriaxone disodium salt;Cephtriaxone;Ceroneed;Disodiumceftriaxone;Lendacin;Longaceph;Monocef;Oframax;Ro 13-9904;Rocephin;Sefirom;Tartriakson;X 13-9904;Ceftriaxone Sodium Hydrate; |
| EINECS: | 277-930-0 |
| PSA: | 296.63000 |
| LogP: | -2.03600 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 90221-55-92-bromo-5-methylbenzaldehyde
- 885590-99-82,3-DIFLUORO-4-IODOBENZALDEHYDE
- 97730-31-9(S)-4'-(2-Methylbutyl)Biphenyl-4-Carbonitrile
| Conditions | Yield |
|---|---|
| Stage #1: C11H15N3O4S; C12H13N5O5S2*C5H13N3 With sodium acetate In water at -50 - -40℃; for 1h; Stage #2: In acetone at 20 - 25℃; for 1h; Solvent; Reagent/catalyst; | 97% |
- 80756-85-0
(Z)-S-benzo[d]thiazol-2-yl 2-(2-aminothiazol-4-yl)-2-(methoxyimino)ethanethioate
- 58909-56-1
7-aminoceftrizine
- 74578-69-1
ceftriaxone disodium
| Conditions | Yield |
|---|---|
| Stage #1: (Z)-S-benzo[d]thiazol-2-yl 2-(2-aminothiazol-4-yl)-2-(methoxyimino)ethanethioate; 7-aminoceftrizine With triethylamine In methanol at -2 - 3℃; Stage #2: With sodium 2-ethylhexanoic acid In water; isopropyl alcohol at 26 - 30℃; for 2h; Product distribution / selectivity; | 95.5% |
| With sodium metabisulfite; edetate disodium; triethylamine In ethanol; water at 1 - 3℃; for 3h; Time; | 91% |
- 58909-56-1
7-aminoceftrizine
- 74578-69-1
ceftriaxone disodium
| Conditions | Yield |
|---|---|
| Stage #1: 7-aminoceftrizine With N,O-bis-(trimethylsilyl)-acetamide In dichloromethane at 20℃; for 2h; Stage #2: diethylthiophosphoryl-(Z)-(2-aminothiazol-4-yl)methoxyimino acetate In dichloromethane at 20℃; for 4h; Stage #3: With sodium hydroxide In dichloromethane; water at 15 - 20℃; pH=7.5 - 7.8; | 94.6% |
| Stage #1: 7-aminoceftrizine With chloro-trimethyl-silane; 1,1,1,3,3,3-hexamethyl-disilazane In dichloromethane at 20℃; for 2h; Stage #2: diethylthiophosphoryl-(Z)-(2-aminothiazol-4-yl)methoxyimino acetate In dichloromethane at 20℃; for 18h; | |
| Stage #1: 7-aminoceftrizine With N,O-bis-(trimethylsilyl)-acetamide In DMF (N,N-dimethyl-formamide) at 20℃; for 2h; Stage #2: diethylthiophosphoryl-(Z)-(2-aminothiazol-4-yl)methoxyimino acetate In DMF (N,N-dimethyl-formamide) at 20℃; for 4h; Stage #3: With sodium hydroxide In DMF (N,N-dimethyl-formamide); water at 15 - 20℃; pH=7.5 - 7.8; | |
| Stage #1: 7-aminoceftrizine With N,N'-bis(trimethylsilyl)urea In dichloromethane at 20℃; for 2h; Stage #2: diethylthiophosphoryl-(Z)-(2-aminothiazol-4-yl)methoxyimino acetate In dichloromethane at 20℃; for 10h; Stage #3: With sodium hydroxide In dichloromethane; water at 15 - 20℃; pH=7.5 - 7.8; |
- 91868-79-0
2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetic acid
- 58909-56-1
7-aminoceftrizine
- 74578-69-1
ceftriaxone disodium
| Conditions | Yield |
|---|---|
| Stage #1: 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetic acid With isopropyl chloroformate; triethylamine In dichloromethane; acetonitrile at -5 - 20℃; for 5h; Stage #2: 7-aminoceftrizine In dichloromethane; acetonitrile at 20℃; for 6h; | 89.18% |
- 73384-59-5, 92143-31-2
ceftriaxone
- 74578-69-1
ceftriaxone disodium
| Conditions | Yield |
|---|---|
| Stage #1: ceftriaxone With triethylamine In water at 0 - 5℃; Stage #2: With sodium 2-ethylhexanoic acid In water; acetone at 0 - 5℃; | 77% |
| With sodium 2-ethylhexanoic acid In water; acetone at -10 - 20℃; for 1.5h; | |
| Stage #1: ceftriaxone With sodium 2-ethylhexanoic acid In water at 10 - 15℃; Stage #2: In water; acetone at 18 - 20℃; for 1.5h; | |
| Stage #1: ceftriaxone With RELITE CNS carboxylic resin; sodium form of In water; acetone at 10℃; for 4h; Stage #2: In water |
- 108260-00-0
7-aminocephalosporanic acid
- 74578-69-1
ceftriaxone disodium
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1.1: acetonitrile 1.2: -15 °C 2.1: sodium acetate / water / 1 h / -50 - -40 °C 2.2: 1 h / 20 - 25 °C View Scheme |
| Conditions | Yield |
|---|---|
| In methanol for 3h; Reflux; |
| Conditions | Yield |
|---|---|
| In methanol for 3h; Reflux; |
| Conditions | Yield |
|---|---|
| In methanol for 3h; Reflux; |
| Conditions | Yield |
|---|---|
| In methanol for 3h; Reflux; |
- 152628-03-01H-Benzimidazole-5-carboxylicacid, 7-methyl-2-propyl-
- 1074-82-4Potassium phthalimide
- 920-66-12-Propanol,1,1,1,3,3,3-hexafluoro-
- 12054-85-2Ammonium molybdate tetrahydrate
- 627-30-53-Chloro-1-propanol
- 31430-15-6Flubendazole
- 105-45-3Butanoic acid, 3-oxo-,methyl ester
- 113-24-6Sodium pyruvate
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
The Ceftriaxone Sodium is an organic compound with the formula C18H18N8Na2O7S3. The systematic name of this chemical is disodium (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-[(6-hydroxy-2-methyl-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. With the CAS registry number 74578-69-1, it is also named as Ceftriaxone disodium.
You can still convert the following datas into molecular structure:
(1)SMILES: Cn1c(nc(=O)c(n1)O)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/c4csc(n4)N)SC2)C(=O)O.[Na+].[Na+]
(2)InChI: InChI=1/C18H18N8O7S3.2Na/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32);;/q;2*+1/b24-8-;;/t9-,15-;;/m1../s1
(3)InChIKey: FDRNWTJTHBSPMW-BBJOQENWBW
(4)Std. InChI: InChI=1S/C18H18N8O7S3.2Na/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32);;/q;2*+1/b24-8-;;/t9-,15-;;/m1../s1
(5)Std. InChIKey: FDRNWTJTHBSPMW-BBJOQENWSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | intravenous | > 3gm/kg (3000mg/kg) | Drugs in Japan Vol. -, Pg. 676, 1995. | |
| infant | TDLo | intramuscular | 16mg/kg/3D-I (16mg/kg) | BRAIN AND COVERINGS: MENINGEAL CHANGES BLOOD: CHANGES IN LEUCOCYTE (WBC) COUNT | Clinical Pediatrics Vol. 32, Pg. 360, 1993. |
| man | TDLo | multiple routes | 800mg/kg/49D- (800mg/kg) | BLOOD: AGRANULOCYTOSIS BLOOD: CHANGES IN LEUCOCYTE (WBC) COUNT | Israel Journal of Medical Sciences. Vol. 29, Pg. 52, 1993. |
| mouse | LD50 | intravenous | 2200mg/kg (2200mg/kg) | Journal of Antibiotics. Vol. 33, Pg. 783, 1980. | |
| mouse | LD50 | oral | > 10gm/kg (10000mg/kg) | "Ceftriaxon Vol. -, Pg. 91, 1982. | |
| mouse | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | "Ceftriaxon Vol. -, Pg. 91, 1982. | |
| rat | LD50 | intravenous | 1900mg/kg (1900mg/kg) | "Ceftriaxon Vol. -, Pg. 91, 1982. | |
| rat | LD50 | oral | > 10gm/kg (10000mg/kg) | "Ceftriaxon Vol. -, Pg. 91, 1982. | |
| rat | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | "Ceftriaxon Vol. -, Pg. 91, 1982. | |
| women | TDLo | multiple routes | 640mg/kg/32D- (640mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: AGRANULOCYTOSIS | Israel Journal of Medical Sciences. Vol. 29, Pg. 52, 1993. |